Clinical Trials

124 enrolled

DermatologicGynecologicHead & NeckThoracic

NSCLC

NCT06975293 2026-03-05

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

Phase 1/2 Recruiting

188 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT05888402 2026-02-27

InTRist

50 enrolled

Phase 2/3 Active not recruiting

Local Advanced Non-small Cell Lung Cancer

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

120 enrolled

NSCLC

NCT07308379 2025-12-29

Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer

Not yet recruiting

1,200 enrolled

Phase 2 Active not recruiting

SCLC, Extensive Stage

NCT06293690 2025-12-18

Toripalimab Combined With SBRT for NSCLC

40 enrolled

Non-small Lung Cancer

NCT07286942 2025-12-16

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Phase 1/2 Completed

119 enrolled

Advanced Lung Cancer

NCT07251582 2025-11-26

LungTime-C02

Phase 3 Recruiting

156 enrolled

GastrointestinalGenitourinaryThoracic

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

NCT04374877 2025-11-10

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Phase 1 Completed

145 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT05386888 2025-10-02

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

Phase 2 Completed

65 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06623136 2025-09-26

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07169994 2025-09-12

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

414 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06127303 2025-09-05

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07039656 2025-08-07

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

211 enrolled

Stage IB-IIIB NSCLC

NCT07097948 2025-08-01

Adjuvant

40 enrolled